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Abstract 
BACKGROUND: Insomnia is a symptom complex that comprises difficulties falling asleep, staying asleep or non-
refreshing sleep in combination with daytime dysfunction or distress. Most people experience insomnia at some 
time during their lives. Because of its high incidence, and also because its symptoms are usually mild and 
transient, the importance of insomnia is frequently underestimated. Various conditions are associated with 
insomnia and can contribute to its development. They can be related to neurological or psychiatric disorders, 
which in turn may be aggravated by a deficiency of restorative sleep and daytime fatigue. 
AIM: In this study, the authors compare the hypnotically effect of Flurazepam and Zolpidem applied on psychiatric 
cases treated in the Mental Health Centre “Prolet” in Skopje, Republic of Macedonia.  
METHODS: The investigation covers 45 patients who have insomnia, in addition to their primary mental illness. 
Тhe examination took six weeks, and it was divided into 3 equal phases. In the first phase of three weeks, 
Zolpidem was used, and in the third phases, Flurazepam was administrated. We used a self-estimating scale of 
13 items and methods of global clinical estimation in the evaluation of received effects. 
RESULTS: The results show that referring to the induction of the sleeping period, its duration and quality and the 
number of awakenings, there are no significant differences between the two medicaments used, but there was a 
significant difference between hypnotic medicaments and placebo. 
CONCLUSION: The termination with the therapy, didn`t lead to the appearance of abstinential symptoms. 
 
 
 
 
Introduction 
 
Sleep medicine has been emerging with more 
public concerns over the past quarter-century, which 
involves multidisciplinary fields of specialists, including 
pulmonology, neurology, cardiology, otolaryngology, 
psychology, psychiatry, endocrinology, geriatrics, 
paediatrics, dentistry, physiology, pharmacology, and 
even alternative medicine. Among a wide variety of 
sleep disorders, insomnia is a particular example that 
heavily involves multidisciplinary efforts. Insomnia is 
highly prevalent in clinical practice, independently or 
comorbidity with another medical or psychiatric 
disorder [1], [2], and its management usually involves 
clinicians or specialists from various academic 
backgrounds. 
Insomnia is a symptom complex that 
comprises difficulties falling asleep, staying asleep or 
non-refreshing sleep in combination with daytime 
dysfunction or distress. The symptom complex can be 
an independent disorder (primary insomnia) or the 
result of another condition (secondary insomnia) [3]. 
Insomnia is commonly divided into 3 types based on 
duration. Transient insomnia lasts up to 1 week and is 
often referred to as adjustment sleep disorder 
because it is caused most often by acute situational 
stress, such as a test or deadline. It is often recurrent 
with the same or similar stresses. The second type, 
short-term insomnia, by definition, lasts 1 to 6 months 
and is usually associated with more persistent 
stressful situational (death or illness) or environmental 
(noise) factors. Finally, chronic insomnia is insomnia 
lasting more than 6 months. 
Most people experience insomnia at some 
time during their lives. Because of its high incidence, 
and also because its symptoms are usually mild and 
transient, the importance of insomnia is frequently 
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underestimated. However, as a chronic disorder, 
which affects about 10% of the population, its 
treatment is often challenging and, moreover, it is 
associated with a substantial number of comorbid 
symptoms [4], [5], [6]. Various conditions are 
associated with insomnia and can contribute to its 
development. They can be related to neurological or 
psychiatric disorders, which in turn may be 
aggravated by a deficiency of restorative sleep and 
daytime fatigue. Insomnia can also result from a 
primary dysfunction or an age-related decline in the 
circadian system. 
Insomnia is characterized by one or more of 
the following: difficulty falling asleep [e.g. sleep onset 
latency (SOL) of more than 30 minutes], insufficient 
sleep [e.g. total sleep time (TST) of less than 5.5 – 6 
hours], numerous nocturnal awakenings, early 
morning awakenings with inability to resume sleep, or 
non-restorative sleep. Common daytime complaints 
include somnolence, fatigue, irritability, and difficulty 
concentrating and performing everyday tasks. 
Because insomnia is associated with reductions in 
attention span, affected individuals can often be 
impulsive and experience impaired judgment, and 
thus are at an increased risk for having injuries at 
home or work, or involvement in accidents while 
driving. Psychiatric and other medical illnesses, 
including cardiovascular diseases, weight gain and 
glucose intolerance, are other conditions which 
include insomnia in their overall symptom complex [7]. 
The International Classification of Sleep 
Disorders (ICSD-2) [8] considers severity criteria as a 
guide to be applied in conjunction with consideration 
of the patient’s clinical status. Mild insomnia refers to 
complaints of an insufficient amount of sleep almost 
every night or of not feeling rested the following day. 
There is little or no impairment in social and / or 
occupational functioning. Moderate and severe 
insomnia refers to complaints of experiencing an 
insufficient amount of sleep every night or of not being 
rested after the impaired sleep episode, accompanied 
by moderate and severe impairment of social and/or 
occupational functioning, respectively. The challenge 
for clinical treatment is to select the therapy, which is 
most appropriate for these differing degrees of 
severity. 
The last several decades have seen an 
evolution in thinking about the classes of medications 
which are to be preferred for treating insomnia. The 
benzodiazepines (BZDs) were introduced in the 1970s 
and rapidly increased in popularity because of their 
efficacy and better safety compared to the 
barbiturates, carbamates, chloral derivatives and 
methaqualone [9]. In recent years, however, 
prescriptions for BZDs have progressively declined, 
especially because of their associated side effect 
profile, including their tendency to promote 
dependence, the occurrence of rebound insomnia 
following the withdrawal of short- and intermediate-
acting derivatives, and the loss of efficacy after 
several weeks of treatment. The clinical need for 
medications which did not have these side effects was 
an important factor leading to the development of 
structurally dissimilar non-BZD hypnotics. These 
included the sedating antihistamines, the melatonin 
receptor agonists ramelteon and tasimelteon, certain 
antidepressants, and the so-called z-drugs, i.e. the 
cyclopyrrolones zopiclone and eszopiclone, the 
pyrazolopyrimidine zaleplon, and the imidazopyridine 
derivative, zolpidem, imidazole. 
Flurazepam (flurazepam hydrochloride), a 
benzodiazepine derivative, is a hypnotic agent which 
does not appear to decrease dream time as measured 
by rapid eye movements (REM). Flurazepam 
decreases sleep latency and several awakenings for a 
consequent increase in total sleep time.  
The duration of hypnotic effect and the profile 
of unwanted effects may be influenced by the alpha 
(distribution) and beta (elimination) half-lives of the 
administered drug and any active metabolites formed. 
When half-lives are long, the drug or metabolite may 
accumulate during periods of nightly administration 
and be associated with impairments of cognitive and 
motor performance during waking hours. If half-lives 
are short, the arid drug metabolites will be cleared 
before the next dose is ingested, and carry-over 
effects related to sedation or CNS depression should 
be minimal or absent. However, during nightly use 
and for an extended period, pharmacodynamic 
tolerance or adaptation to some effects of 
benzodiazepine hypnotics may develop. If the drug 
has a very short elimination half-life, it is possible that 
a relative deficiency (i.e., about the receptor site) may 
occur at some point in the interval between each 
night's use. This sequence of events may account for 
two clinical findings reported to occur after several 
weeks of nightly use of rapidly eliminated 
benzodiazepine hypnotics: 1) increased wakefulness 
during the last third of the night; and 2) the 
appearance of increased daytime anxiety. Flurazepam 
is a benzodiazepine with a long half-life [10]. 
Zolpidem has proved to be a suitable 
hypnotic, especially about efficacy in sleep initiation. 
As will be discussed below, it is relatively well 
tolerable and almost devoid of the side effects 
typically associated with BDZs. The low incidence of 
side effects is, in part, a consequence of a relatively 
short half-life in the circulation. At usual doses of 
immediate-release (IR) Zolpidem, the peak plasma 
concentrations are attained between about 45 min 
and 2 h after intake [11], a kinetics profile that 
corresponds well with the time course of psychomotor 
tests, in which the maximum efficacy was found 
around 1.5 h followed by a rapid decline [12]. The 
pharmacokinetics of such a short-acting drug, when 
given as an IR formulation, maybe not ideal in terms 
of promoting sleep maintenance. To respond to the 
clinical need for an agent which could reduce the 
number of nocturnal awakenings, Zolpidem extended-
release was developed. 
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In this study, we want to compared the effects 
of two drugs Flurazepam-15 mg and Zolpidem -10 mg 
at psychiatric patients with sleeping disturbance. 
 
 
Material and Methods 
 
A blind, placebo-controlled, comparative study 
was made. The study lasted for six weeks. 
The study involved 45 patients, divided into 
three equals phase (two weeks each), in the first 
phase receiving zolpidem, in the second phase-
placebo only, and in the third phase was 
administrated-flurazepam only as an evening therapy. 
35 (77.8%) of them had diagnosis schizophrenia, and 
10 (22.2%) had psychosis. Thirty (66.7%) were men, 
and 15 (33.3%) were women. The average age is 
42.5 y., ranging from 36 to 56 (minimum 36 у and a 
maximum of 56 у). The drugs are taken at night 
before bedtime. 
The patients were informed about the study, 
and they had to follow the investigator instructions. 
Patients were instructed not to nap or drink alcohol 
during the weeks of the study, or to consume food or 
caffeinated beverages after 7:00 p.m. 
We used self-administrative questioner to 
evaluation the effects of 13 items. Every day the 
quality of sleeping was estimated by the authors and 
patients helped by standardised questionnaires. The 
question referred to sleeping induction; it`s duration 
and quality, several awakenings through the night, 
subjective fill in-of “good rest”, hangover, tiredness 
through the day. One week after the third phase 
patients were observed whether should appear any 
abstinential symptoms. 
Answers were summarised and statistically 
evaluated. Statistical analysis of quantitative data was 
performed by an analysis of variance (ANOVA) for 
repeated measures. In those cases, in which the 
ANOVA showed a significant drug effect, comparisons 
between individual treatments were performed by a 
post hoc least significant difference test. Categorical 
data were assessed by the use of chi-square tests 
and Fisher exact 2 tailed. 
There were no reports of amnesia, 
disorientation, hallucinations or other major side 
effects. 
 
 
Results 
 
Results showed that the active drugs were 
efficient in controlling insomnia. 
Both drugs improved a measure of "how good 
a night's sleep", and zolpidem improved the score on 
a question of "how rested do you feel". There was a 
trend for both compounds to reduce "difficulty getting 
to sleep" (Table 1). 
TABLE 1: Drug-induced changes in subjective measures of 
sleep over the entire night as seen on the Morning Sleep 
Questionnaire 
 Placebo Flurazepam Zolpidem P 
How good a night's sleep?
a
  2.3 ± 0.4 3.2 ±0.3* 3.2 ± 0.3* < 0.05 
How rested do you feel?
b 
 1.2 ± 0.2 1.5 ± 0.2 1.8 ± 0.2* < 0.05 
Difficulty getting to sleep?
'c
 3.0 ± 0.2 2.2 ± 0.3 2.1 ± 0.4 > 0.05 
"p" values in the right-hand column refer to the results of an analysis of variance; 
a 
= very 
poor; 2 = poor; 3 = usual quality; 4 = excellent; 
b 
= much less rested; 2 = rested as usual; 3 
= much more rested; 
c
 = less difficult; 2 = usual amount; 3 = more difficult; 4 = didn't sleep; 
* Differs from placebo by p < 0.05 by post hoc least significant difference test. 
 
The results of this trial/study show that there 
is no statistically significant difference between 
Zolpidem and Flurazepam referred to the induction of 
sleep. Significant differences appear between the 
hypnotics and placebo (Table 2).  
Table 2: Comparison between periods of investigation 
 Placebo 
Fluraz
epam 
Zolpidem F/P p Z/P p F/Z p 
1. How much time you 
need to fall asleep 
≤ 30min 10 37 36 < 0.05 < 0.05 > 0.05 
> 30min. 35 8 9 
2. How you fall asleep fast 10 37 36 < 0.05 < 0.05 > 0.05 
slow 35 8 9 
3. Habitual total sleep 
time (hours) 
> 5h 11 39 35 < 0.05 < 0.05 > 0.05 
< 5h 34 6 10 
4. Do you feel sleepy 
enough 
yes 11 39 35 < 0.05 < 0.05 > 0.05 
no 34 6 10 
5. How many times did 
you wake during the 
night 
0 - 1 12 39 36 < 0.05 < 0.05 > 0.05 
> 2 33 6 9 
6. How you slept well 10 40 37 < 0.05 < 0.05 > 0.05 
bad 35 5 8 
7. You wake up easy 36 41 40 > 0.05 > 0.05 > 0.05 
difficult 9 4 5 
8. How do you feel 
after waking up 
good 29 39 31 < 0.05 > 0.05 < 0.05 
bad 16 6 14 
9. Do you dream yes 32 37 35 > 0.05 > 0.05 > 0.05 
no 13 8 10 
10. Do you feel tired 
through the day 
yes 18 9 15 < 0.05 > 0.05 > 0.05 
 
Significant differences appear between the 
Flurazepam and placebo at Q1-6 and Q8, not 
significant at Q7 and Q9-10(SS Q1 and Q2: chi 
square = 32.4641, p = 0.000000; Q3 and Q4: chi 
square = 35.2800, p = 0.000000; Q5: chi square = 
32.4641, p = 0.000000; Q6: chi square = 40.500, p = 
0.000000; Q8: chi square = 6.0160, p = 0.014176; 
Q10: chi square = 4.2857, p = 0.0384339; NS Q7: chi 
square = 2.2478, p = 0.13.3808; Q9: chi square = 
1.5528, p = 0.212723;). 
Significant differences appear between the 
Zolpidem and placebo at Q1-6, not significant at Q7-
10(SS Q1 and Q2: chi square = 30.0593, p = 
0.000000; Q3 and Q4: chi square = 26.9720, p = 
0.000000; Q5: chi square = 21,7143, p = 0.000000; 
Q6: chi square = 32.4641, p = 0.000000; NS Q7: chi 
square = 1.3534, p = 0.244680; Q8: chi square = 
0.2000, p = 0.654720; Q9: chi square = 0.5256, p = 
0.468448; Q10: chi square = 4.2857, p = 0.511683). 
Significant differences appear between the 
Zolpidem and Flurazepam at Q8 (SS Q8: chi square = 
4.1143, p = 0.042522), Not significant at Q1-7 and 
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Q9-10 (NS Q1 and Q2: chi square = 0,0725, p = 
0.787699; Q3 and Q4: chi square =1,2162, p = 
0.270104; Q5: chi square = 0.7200, p = 0.396143; Q6: 
chi square = 0.8092, p = 0.368595; Q7: Fisher exact 2 
tailed p = 0.5; Q9: chi square = 0.2778, p = 0.598161; 
Q10: chi square = 2.0455, p = 0.152661). 
Total sleeping time for both tested hypnotic 
drugs is approximately equal but significantly longer 
than the time when placebo administrated. The 
subjective judgment of the quality of sleep did not 
show a significant difference between the two 
hypnotics as well. Experience of “sleeping well” 
(pleasant dream) was present in both cases. 
Dreaming was also present. 
Several “wakenings” was significantly lower 
when the hypnotic was administrated compared to 
placebo, which corresponds with the subjective 
judgment of the quality of the sleep. 
Difficulties with morning wake up described as 
dizziness, hangover, drowsiness frequently present 
when Zolpidem was used, which was statistically as a 
not significant difference. 
Daily tiredness and drowsiness particularly in 
the afternoon as a side effect appeared with 
Zolpidem, which was statistically as a not significant 
difference. 
During the administration of both drugs, 
worsening of the principal disorder did not occur, as 
well as any somatic complication. Interruption of 
Flurazepam treatment did not cause abstinential 
difficulties. 
 
 
Discussion 
 
Individuals have different opinions they sleep 
well or not. Sleeping well usually means short time “to 
fall asleep” few times wreaking up through the night, 
filling for “good rest” in the morning, opposite to 
“sense of tiredness” in lack of sleeping [13], [14]. The 
“ideal hypnotic drug” has to ensure quick falling 
asleep, permanent sleeping for 6-8h, without side 
effects in the next day [2], [15]. In the psychiatric 
population, we often meet insomnia as initial one, in 
introductory and developed form of psychosis, such, 
also as terminal in depression. 
At the beginning of treatment, hypnotics are 
commonly administrated besides other antipsychotic 
or antidepressant therapy. 
Insomnia is a frequent symptom in everyday 
psychiatric practise and prescribing hypnotic 
medicines as well. Because of this, there are specific 
risks for developing psychophysical addiction and 
possibility for suicide abuse, before prescribing 
priority, it is necessary to estimate ethyology and 
possibility for correction of the causes. 
Global statistical analysis regarding all 
parameters shows the equivalence of both of the 
hypnotics. Basic qualities of the used drugs, 
efficiency, tolerance and compatibility are present in 
both of them, but there is a difference in favour of 
Flurazepam in terms of better tolerance. 
About recommendations in the treatment of 
insomnia, one should have to distinguish between the 
different causes and clinical phenomenology of the 
various forms of this disorder. If sleep disturbances 
are primarily associated with psychiatric disorders, in 
particular, depression, the usefulness of hypnotics 
needs to be carefully monitored, and interference with 
antidepressants has to be taken into consideration. 
Zolpidem may be used and has already been 
successfully tested in MDD [16], [17], [18] and GAD 
[19], but due caution is still recommended for long-
term treatment [20], [21]. In these cases, a drug like 
agomelatine may be an alternative medication of 
choice, in as much as it combines sleep-inducing, 
melatoninergic properties with actions of an 
antidepressant [22], [23], [24]. 
Most of the patients chronically use hypnotics 
together with other psychotropic drugs, so this 
examination does not fill full all requirements from a 
pharmacological point of view which we should 
consider and also commonly used a combination of 
medicaments should be considered as well. 
The perceived and measured effectiveness of 
Zolpidem and Fluarezepam in decreasing sleep 
latency, increasing and maintaining sleep duration, 
and improving sleep quality without causing significant 
side effects or affecting next day performance 
suggests that Zolpidem and Fluarezepam are 
important in the treatment of insomnia. 
To conclude Flurazepam beside its clinically 
equal efficiency as Zolpidem, most common hypnotic 
drug, has an advantage with good tolerance and the 
possibility of safe combination with antipsychotic or 
antidepressant medicines. But still, psychiatric 
observation and control are often necessary also 
reduction or discontinuing the usage as prevention to 
a possible threat of addiction particularity in risk 
cases. Adverse effects are moderate, frequently in the 
incidence range of placebos, and certainly less 
frequent and severe. 
We had a very similar conclusion with Montie 
et al. [16]. The evaluation and management of 
insomnia are often challenging. Insomnia is a 
multidimensional disorder, and consequently, any 
approach to its management should consider a 
combination of both pharmacological and non-
pharmacological measures. In practice, 
pharmacological approaches tend to be used with 
greater frequency than psychotherapy and other 
treatment methods. In patients with chronic insomnia 
and a coexisting psychiatric, neurologic or medical 
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condition, the underlying disorder needs to be treated 
appropriately [16]. 
Insomnia involves multidisciplinary fields of 
research. In recent years, advances have been made 
in the understanding of insomnia and its treatment 
options [2], [25]. However, the breakdown of 
disciplinary boundaries makes it more difficult for 
scientists or clinicians to reconcile all of the 
publications relevant to their research [2], [26]. We 
recommend that both pharmacological and 
nonpharmacological treatment for insomnia can have 
great potential for advancement in future years. 
Although sedative and hypnotic drugs dominated 
insomnia treatment for a long time, 
nonpharmacological therapies such as cognitive 
behavioural therapy have attracted considerable 
attention in recent years, for the benefits of reducing 
dosage and side effects of medication and providing 
alternative options. Also, the treatment efficacy and 
clinical outcome were not equally established for 
insomnia treatment modalities.  
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